Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received July 15, 2010
- Accepted after revision September 9, 2010
- Published online May 13, 2011.
Article Versions
- Latest version (February 17, 2011 - 06:53).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright © American Society of Neuroradiology
Author Information
- W.B. Popea,
- A. Laib,
- R. Mehtaa,
- H.J. Kima,
- J. Qiaoa,
- J.R. Younga,
- X. Xuea,
- J. Goldina,
- M.S. Browna,
- P.L. Nghiemphub,
- A. Tranb and
- T.F. Cloughesyb
- aFrom the Departments of Radiological Sciences (W.B.P., R.M., H.J.K., J.Q., J.R.Y., X.X., J.G., M.S.B.)
- bNeurology (A.L., P.L.N., A.T., T.F.C.), David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California.
- Please address correspondence to Whitney B. Pope, MD, PhD, Department of Radiological Sciences, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, BL-428 CHS, Los Angeles, CA 90095-1721; e-mail: wpope{at}mednet.ucla.edu
Altmetrics
Cited By...
In this issue
Apparent Diffusion Coefficient Histogram Analysis Stratifies Progression-Free Survival in Newly Diagnosed Bevacizumab-Treated Glioblastoma
Jump to section
Related Articles
Cited By...
- Prognostic Implications of Gadolinium Enhancement of Skull Base Chordomas
- Correlation of 18F-FDG PET and MRI Apparent Diffusion Coefficient Histogram Metrics with Survival in Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium
- ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI
- Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI
- The Added Prognostic Value of Preoperative Dynamic Contrast-Enhanced MRI Histogram Analysis in Patients with Glioblastoma: Analysis of Overall and Progression-Free Survival
- Lessons From Anti-Vascular Endothelial Growth Factor and Anti-Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma
- Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma
- Diffusion-Weighted Imaging in Cancer: Physical Foundations and Applications of Restriction Spectrum Imaging
- A Prognostic Model Based on Preoperative MRI Predicts Overall Survival in Patients with Diffuse Gliomas
- Pretreatment ADC Histogram Analysis Is a Predictive Imaging Biomarker for Bevacizumab Treatment but Not Chemotherapy in Recurrent Glioblastoma
- Diffusion-Weighted MR Imaging and MGMT Methylation Status in Glioblastoma: A Reappraisal of the Role of Preoperative Quantitative ADC Measurements
- Do Imaging Biomarkers Relate to Outcome in Patients Treated with VEGF Inhibitors?